Join us Thursday, Oct. 17, for this instructive webinar providing practical insights you can use immediately in your lab. You’ll discover:
- The Principal Goal of Bioequivalence (BE)
- Challenges in Topical Generic Drug Development
- Current Approaches and Guidelines for BE of Topical Drug Products in the U.S. and E.U.
- Role of IVRT Method as Surrogate Alternative and Fundamentals of IVRT
- Case Studies
Your expert presenter will be Dr. Theo Kapanadze, co-founder and chief scientific officer of Diteba Inc., a leader in dermal and transdermal research services that has been pivotal in advancing drug development and securing numerous innovator and generic drug approvals. Dr. Kapanadze earned his Ph.D. and D.Sc. in the chemistry of biological active compounds and has 20-plus years of research experience in analytical R&D chemistry and the pharmaceutical, biopharmaceutical, and nutraceutical industries.
Following the 45-minute webinar, Dr. Kapanadze will provide answers to significant common questions in a Q&A format. You’re certain to benefit from this session:
- Gain a comprehensive understanding of the principles and methodologies involved in IVRT
- Learn about the latest regulatory guidelines and requirements from the FDA and EMA.
- Explore case studies demonstrating practical applications of IVRT.
- Acquire insights into current challenges and future directions in topical product bioequivalence.
